"Molecular switches" on mGluR allosteric ligands that modulate modes of pharmacology

Biochemistry

Volumn 50, Issue 13, 2011, Pages 2403-2410

  Wood, Michael R ^a,b,c   Hopkins, Corey R ^a,b,c   Brogan, John T ^a,b   Conn, P Jeffrey ^a,c   Lindsley, Craig W ^a,b,c  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOSTERIC MODULATORS; ALLOSTERIC SITE; DENSENSITIZATION; DOWN-REGULATION; DRUG CANDIDATES; DRUG DISCOVERY; DRUG TARGETS; FUNCTIONAL ASSAYS; G PROTEIN COUPLED RECEPTORS; METABOTROPIC GLUTAMATE RECEPTORS; MOLECULAR SWITCHES; PHYSIOLOGICAL CONDITION; SIDE EFFECT; STRUCTURAL CHANGE;

DRUG INTERACTIONS; METABOLISM;

LIGANDS;

G PROTEIN COUPLED RECEPTOR; METABOTROPIC RECEPTOR;

ALLOSTERISM; ARTICLE; DESENSITIZATION; DOWN REGULATION; DRUG METABOLISM; DRUG TRAFFIC; HUMAN; INTERNALIZATION; MODULATION; MOLECULAR DYNAMICS; MOLECULAR SWITCH; PHARMACOLOGY; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ALLOSTERIC REGULATION; ANIMALS; DRUG DESIGN; DRUG INTERACTIONS; HUMANS; LIGANDS; RECEPTORS, METABOTROPIC GLUTAMATE; SIGNAL TRANSDUCTION;

EID: 79953213637     PISSN: 00062960     EISSN: 15204995     Source Type: Journal    
DOI: 10.1021/bi200129s     Document Type: Article

References (53)

1. George, S. R., O'Dowd, B. F., and Lee, S. P. (2002) G-protein-coupled receptor oligomerization and its potential for drug discovery Nat. Rev. Drug Discovery 1, 808-820 (Pubitemid 37361564)
2. Filmore, D. (2004) It's a GPCR world Mod. Drug Discovery 7, 24-28
3. Hopkins, A. L. and Groom, C. R. (2002) The druggable genome Nat. Rev. Drug Discovery 1, 727-730 (Pubitemid 37361545)
4. Cabrera-Vera, T. M., Vanhauwe, J., Thomas, T. O., Medkova, M., Preininger, A., Mazzoni, M. R., and Hamm, H. E. (2003) Insights into G protein structure, function and regulation Endocr. Rev. 24, 765-781 (Pubitemid 38067698)
5. Bridges, T. M. and Lindsley, C. W. (2008) G-protein coupled receptors: From classical modes of modulation to allosteric mechanisms ACS Chem. Biol. 3, 530-542
6. Overington, J. P., Al-Lazikani, B., and Hopkins, A. L. (2006) How many drug targets are there? Nat. Rev. Drug Discovery 5, 993-996 (Pubitemid 44835126)
7. Cartnell, J. and Schoepp, D. D. (2000) Regulation of neurotransmitter release by metabotropic glutamate receptors J. Neurochem. 75, 889-907 (Pubitemid 30660476)
8. Conn, P. J. and Pin, J.-P. (1997) Pharmacology and functions of metabotropic glutamate receptors Annu. Rev. Pharmacol. Toxicol. 37, 205-237 (Pubitemid 27238875)
9. Schoepp, D. D., Jane, D. E., and Monn, J. A. (1999) Pharmacological agents acting at subtypes of metabotropic glutamate receptors Neuropharmacology 38, 1431-1476 (Pubitemid 29457728)
10. Conn, P. J., Christopolous, A., and Lindsley, C. W. (2009) Allosteric Modulators of GPCRs as a Novel Approach to Treatment of CNS Disorders Nat. Rev. Drug Discovery 8, 41-54
11. Lewis, J. A., Lebois, E. P., and Lindsley, C. W. (2008) Allosteric modulators of kinases and GPCRs. Design principles and structural diversity Curr. Opin. Chem. Biol. 12, 269-279
12. Smith, N. J., Bennett, K. A., and Milligan, G. (2011) When simple agonism is not enough: Emerging modalities of GPCR ligands Mol. Cell. Endocrinol. 331, 241-247
13. Rocheville, M. and Garland, S. L. (2010) An industrial perspective on positive allosteric modulation as a means to discover safe and selective drugs Drug Discovery Today: Technol. 7, e87-e94
14. Jensen, A. A. and Spalding, T. A. (2004) Allosteric modulation of G-protein coupled receptors Eur. J. Pharm. Sci. 21, 407-420 (Pubitemid 38283914)
15. Christopoulos, A. (2001) Allosteric binding sites on cell-surface receptors: Novel targets for drug discovery Nat. Rev. Drug Discovery 1, 198-215
16. Harrington, P. E. and Fotsch, C. (2007) Calcium sensing receptor activators: Calcimimetics Curr. Med. Chem. 14, 3027-3034 (Pubitemid 350226971)
17. Hizue, M. (2010) Profile of maraviroc: A CCR5 antagonist in the management of treatment-experienced HIV patients HIV/AIDS 2, 151-156
18. Lischig, S., Gasparini, F., Ruegg, D., Stoehr, N., Flor, P. J., Vranesic, I., Prezeau, L., and Pinn, J.-P. (1999) CPCOOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signalling without affecting glutamate binding Mol. Pharmacol. 55, 453-461 (Pubitemid 29128101)
19. Gasparini, F., Lingenhohl, K., Stoehr, N., Flor, P. J., Heinrich, M., and Vranesic, I. (1999) 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGluR5 receptor antagonist Neuropharmacology 38, 1493-1503 (Pubitemid 29457731)
20. Kew, J. N. C. (2004) Positive and negative allosteric modulation of metabotropic glutamate receptors: Emerging therapeutic potential Pharmacol. Ther. 104, 233-244 (Pubitemid 39531928)
21. Chavez-Noriega, L. E., Schaffhauer, H., and Campbell, U. C. (2002) Metabotropic glutamate receptors: Potential drug targets for the treatment of schizophrenia Curr. Drug Targets: CNS Neurol. Disord. 1, 261-281
22. Knoflach, F., Mutel, V., Jolidon, S., Kew, J. N. C., Malherbe, P., Vieria, E., Wichmann, J., and Kemp, J. A. (2001) Positive allosteric modulators of metabotropic glutamate 1 receptor: Characterization, mechanism of action and binding site Proc. Natl. Acad. Sci. U.S.A. 98, 13402-13407 (Pubitemid 33051375)
23. Conn, P. J., Lindsley, C. W., and Jones, C. J. (2009) Allosteric modulation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia Trends Pharmacol. Sci. 30, 25-31
24. Lindsley, C. W., Niswender, C. M., Engers, D. W., and Hopkins, C. R. (2009) Recent progress in the development of mGluR4 positiive allosteric modulators for the treatment of Parkinson's disease Curr. Top. Med. Chem. 9, 949-963
25. Williams, D. L., Jr. and Lindsley, C. W. (2005) Positive allosteric modulators of metabotropic glutamate receptor subtype 5 (mGluR5) Curr. Top. Med. Chem. 5, 825-838
26. Conn, P. J., Jones, C., and Lindsley, C. W. (2009) Subtype selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders Trends Pharmacol. Sci. 30, 148-156
27. Bridges, T. M., Marlo, J. E., Niswender, C. M., Jones, J. K., Jadhav, S. B., Gentry, P. R., Weaver, C. D., Conn, P. J., and Lindsley, C. W. (2009) Discovery of the first highly M5-preferring muscarinic acetylcholine receptor ligand, an M5 positive allosteric modulator derived from a series of 5-trifluoromethoxy N -benzyl isatins J. Med. Chem. 52, 3445-3448
28. 1 PAM Bioorg. Med. Chem. Lett. 20, 1972-1975
29. Lindsley, C. W., Zhao, Z., Leister, W. H., Robinson, R. G., Barnett, S. F., Defeo-Jones, D., Jones, R. E., Hartman, G. D., Huff, J. R., Huber, H. E., and Duggan, M. E. (2005) Allosteric Akt (PKB) kinase inhibitors. Discovery and SAR of isozyme selective inhibitors Bioorg. Med. Chem. Lett. 15, 761-765
30. Scott, S. A., Selvy, P. E., Buck, J., Cho, H. P., Criswell, T. L., Thomas, A. L., Armstrong, M. D., Arteaga, C., Lindsley, C. W., and Brown, H. A. (2009) Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness Nat. Chem. Biol. 5, 108-117
31. Lavieri, R., Scott, S. A., Selvy, P. E., Kim, K., Jadhav, S., Morrison, R. D., Daniels, J. S., Brown, H. A., and Lindsley, C. W. (2010) Design, Synthesis and Biological Evaluation of Halogenated N -(2-(4-Oxo-1-phenyl-1,3,8- triazasprio[4.5]decan-8-yl)ethylbenzamides: Discovery of an Isoform Selective Small-Molecule Phospholipase D2 (PLD2) Inhibitor J. Med. Chem. 53, 6706-6719
32. O'Brien, J. A., Lemaire, W., Chen, T.-B., Chang, R. S. L., Jacobson, M. A., Ha, S. N., Lindsley, C. W., Sur, C., Pettibone, D. J., Conn, P. J., and Wiliams, D. L. (2003) A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5) Mol. Pharmacol. 64 (3) 731-741
33. O'Brien, J. A., Lemaire, W., Wittmann, M., Jacobson, M. A., Ha, S. N., Wisnoski, D. D., Lindsley, C. W., Schaffhauser, H. J., Sur, C., Duggan, M. E., Pettibone, D. J., Conn, J., and Williams, D. L. (2004) A novel selective allosteric modulator potentiates the activity of the native metabotropic glutamate receptor subtype 5 (mGluR5) in rat forebrain J. Pharmacol. Exp. Ther. 309 (2) 568-579
34. Lindsley, C. W., Wisnoski, D. D., Leister, W. H., O'Brien, J. A., Lemiare, W., Williams, D. L., Jr., Burno, M., Sur, C., Kinney, G. G., Pettibone, D. J., Tiller, P. R., Smith, S., Duggan, M. E., Hartman, G. D., Conn, P. J., and Huff, J. R. (2004) Discovery of positive allosteric modulators for the metabotropic glutamate receptor subtype 5 from a series of N -(1,3-Diphenyl-1H-pyrazol-5-yl)benzamides that potentiate receptor function in vivo J. Med. Chem. 47, 5825-5828 (Pubitemid 39507327)
35. Zhao, Z., Wisnoski, D. D., O'Brien, J. A., Lemiare, W., Williams, D. L., Jr., Jacobson, M. A., Wittman, M., Ha, S., Schaffhauser, H., Sur, C., Pettibone, D. J., Duggan, M. E., Conn, P. J., Hartman, G. D., and Lindsley, C. W. (2007) Challlenges in the development of mGluR5 positive allosteric modulators: The discovery of CPPHA Bioorg. Med. Chem. Lett. 17, 1386-1389
36. Kinney, G. G., O'Brien, J. A., Lemaire, W., Burno, M., Bickel, D. J., Clements, M. K., Wisnoski, D. D., Lindsley, C. W., Tiller, P. R., Smith, S., Jacobson, M. A., Sur, C., Duggan, M. E., Pettibone, D. J., and Williams, D. W., Jr. (2005) A novel selective allosteric modulator of metabotropic glutamate receptor subtype 5 (mGluR5) has an antipsychotic profile in rat behavioral models J. Pharmacol. Exp. Ther. 313 (1) 199-208
37. Rodriguez, A. L., Nong, Y., Sekaran, N. K., Alagille, D., Tamagnan, G. D., and Conn, P. J. (2005) A close structural analog of 2-methyl-6- (phenylethynyl)-pyridine acts a neutral allosteric site ligand on metabotropic glutamate receptor subtype 5 and blocks the effects of multiple allosteric modulators Mol. Pharmacol. 68, 1793-1802 (Pubitemid 41654362)
38. Sharma, S., Rodriguez, A., Conn, P. J., and Lindsley, C. W. (2008) Synthesis and SAR of a mGluR5 allosteric partial antagonist lead: Unexpected modulation of pharmacology with slight structural modifications to a 5-(phenylethynyl)pyrimidine scaffold Bioorg. Med. Chem. Lett. 18, 4098-4101
39. Sharma, S., Kedrowski, J., Rook, J. M., Smith, J. M., Jones, C. K., Rodriguez, A. L., Conn, P. J., and Lindsley, C. W. (2009) Discovery of Molecular Switches that Modulate Modes of mGluR5 Pharmacology In Vitro and In Vivo Within a Series of Functionalized 5-(phenylethynyl)pyrimidines J. Med. Chem. 52, 4103-4106
40. Liu, F., Grauer, S., Kelley, C., Navarra, R., Graf, R., Zhang, G., Atkinson, P. J., Wantuch, C., Popiolek, M., Day, M., Khawaja, X., Smith, D., Olsen, M., Kouranova, E., Gilbert, A., Lai, M., Pausch, M. H., Pruthi, F., Pulcicchio, C., Brandon, N. J., Comery, T. A., Beyer, C. E., Logue, S., Rosenzweig-Lipson, S., and Marquis, K. L. (2008) ADX47273 [ S -(4-Fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl] -piperidin-1-yl}-methanone]: A Novel Metabotropic Glutamate Receptor 5-Selective Positive Allosteric Modulator with Preclinical Antipsychotic-Like and Procognitive Activities J. Pharmacol. Exp. Ther. 327, 827-839
41. Engers, D. W., Rodriguez, A. L., Oluwatola, O., Hammond, A. S., Venable, D. F., Williams, R., Sulikowski, G. A., Conn, P. J., and Lindsley, C. W. (2009) Synthesis, SAR and unanticipated pharmacological profiles of analogs of the mGluR5 ago-potentitaor ADX-47273 ChemMedChem 4, 505-511
42. 5 NAMs, PAMs, and partial antagonists. Bioorg. Med. Chem. Lett. 2011, in press.
43. Rodriguez, A. L., Grier, M. D., Jones, C. K., Herman, E. J., Kane, A. S., Smith, R. L., Williams, R., Zhou, Y., Marlo, J. E., Days, E. L., Blatt, T. N., Jadhav, S., Menon, U., Vinson, P. N., Rook, J. M., Stauffer, S. R., Niswender, C. M., Lindsley, C. W., Weaver, C. D., and Conn, P. J. (2011) Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity Mol. Pharmacol. 78, 1105-1123
44. Hammond, A. S., Rodriguez, A. L., Niswender, C. M., Lindsley, C. W., and Conn, P. J. (2010) Discovery of a novel chemical class of allosteric ligands of metaboropic glutamate receptor subtype 5 indicates distinct modes of efficacy as well as a unique interaction with the receptor ACS Chem. Neurosci. 1, 702-716
45. Zhou, Y., Rodriguez, A. L., Williams, R., Weaver, C. D., Conn, P. J., and Lindsley, C. W. (2009) Synthesis and SAR of Novel, Non-MPEP Chemotype mGluR5 NAMs Identified by Functional HTS Bioorg. Med. Chem. Lett. 19, 6502-6506
46. Rodriguez, A. L., Williams, R., Zhou, S., Lindsley, S. R., Le, U., Conn, P. J., and Lindsley, C. W. (2009) Discovery and SAR of Novel mGluR5 Non-Competitive Antagonists not based on an MPEP Chemotype Bioorg. Med. Chem. Lett. 19, 3209-3212
47. 5 potentiators with improved physiochemical properties and efficacy in a rodent model predictive of antipsychotic activity ACS Med. Chem. Lett. 1, 433-438
48. Williams, R., Zhou, Y., Niswender, C. M., Luo, Q., Conn, P. J., Lindsley, C. W., and Hopkins, C. R. (2010) Re-exploration of the PHCCC scaffold: Discovery of improved positive allosteric modulators of mGluR4 ACS Chem. Neurosci. 1, 411-419
49. Schann, S., Mayer, S., Franchet, C., Frauli, M., Steinberg, E., Thomas, M., Baron, L., and Neuville, P. (2010) Chemical switch of a metabotropic glutamate receptor 2 silent allosteric modulator into dual metabotropic glutamate receptor 2/3 negative/positive allosteric modulators J. Med. Chem. 53, 8775-8779
50. Pagano, A., Ruegg, D., Litschig, S., Stoehr, N., Stierlin, C., Heinrich, M., Flooersheim, P., Prezeau, L., Carroll, F., Pin, J.-P., Cambria, A., Vranesic, I., Flor, P. J., Gasparini, F., and Kuhn, R. (2000) The non-competitive antagonists 2-methyl-6-(phenylethynyl)pyridine and 7-hydroxyiminocyclopropan[ b ]chromen-1 a -carboxylic acid ethyl ester interact with overlapping binding pockets in the transmembrane region of group I metabotropic glutamate receptors J. Biol. Chem. 275, 33750-33758
51. Malherebe, P., Kratochwil, N., Zenner, M.-T., Piussi, J., Diener, C., Kratzeisen, C., Fischer, C., and Porter, R. H. P. (2003) Mutational analysis and molecular modeling of the binding pocket of the metabotropic glutamate 5 receptor negative modulator 2-methyl-6-(phenylethynyl)pyridine Mol. Pharmacol. 64, 823-832 (Pubitemid 37153050)
52. Swanson, C. J., Bures, M., Johnson, M. P., Linden, A.-M., Monn, J. A., and Schoepp, D. D. (2005) Metabotropic glutamate receptors as novel targets for anxiety and stress disorders Nat. Rev. Drug Discovery 4, 131-146
53. Digby, G. J., Conn, P. J., and Lindsley, C. W. (2010) Orthosteric- and allosteric-induced ligand-directed trafficking at G protein-coupled receptors Curr. Opin. Drug Discovery Dev. 13, 577-586